The patient was switched to risankizumab, an IL-23 inhibitor, which has proven to be efficacious in inducing and maintaining clinical remission of inflammatory bowel diseases, while being an excellent therapeutic option for psoriasis, as well. The gene discussed is IL37; the disease is inflammatory bowel disease.